San Francisco, United States
Benchling, founded in 2012, is at the forefront of transforming the biotechnology and life sciences sectors. Headquartered in the United States, this innovative platform is redefining biotech R&D for the AI era with a mission to unlock the power of biotechnology, enabling global customers to reach milestones faster.
The company's platform serves as an AI-driven solution that integrates seamlessly into research workflows, allowing scientists to design experiments, capture structured data, and operate AI agents and models. Its impact is significant, with over 200,000 scientists from academic labs to major players like Sanofi and Moderna relying on Benchling.
Benchling's recent funding achievements include a substantial $100.00M Series F investment on 1 November 2021, backed by prominent investors Lone Pine Capital, Altimeter Capital, Franklin Templeton, and Tiger Global. Such backing underscores the platform's promise in reshaping the future of biotech R&D through data-driven and AI-enhanced solutions.
